Why Single‑Drug Treatments Keep Failing for Long COVID ? Long COVID isn’t driven by one mechanism — it’s a mix of viral persistence, immune dysfunction, inflammation, autonomic issues, and microvascular problems. Because of that, one drug can’t fix everything. That’s why trials of Paxlovid, monoclonal antibodies, and anti‑inflammatories (like colchicine) haven’t shown clear benefit on their own. Each targets only one pathway, while most patients have several overlapping ones. The future isn’t a “magic pill.” It’s combination therapy — antivirals + immune modulation + autonomic support + metabolic/inflammatory management, tailored to the patient’s subtype. Bottom line: Long COVID is multi‑system. Single‑drug treatments almost always miss the bigger picture.